SalioGen Therapeutics is moving quickly. Ten months after exiting stealth with $20 million in series A funds, the Massachusetts-based biotech...
SalioGen Therapeutics is moving quickly. Ten months after exiting stealth with $20 million in series A funds, the Massachusetts-based biotech...